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BrainProton NMR spectroscopy is emerging from translational and preclinical neuroscience research as an impor-
tant tool for evidence based diagnosis and therapy monitoring. It provides biomarkers that offer ﬁngerprints
of neurological disorders even in cases where a lesion is not yet observed in MR images. The collection of mol-
ecules used as cerebral biomarkers that are detectable by 1H NMR spectroscopy deﬁne the so-called “neuro-
chemical proﬁle”. The non-invasive quality of this technique makes it suitable not only for diagnostic
purposes but also for therapy monitoring paralleling an eventual neuroprotection. The application of 1H
NMR spectroscopy in basic and translational neuroscience research is discussed here.
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Enormous advances are occurring in the elucidation of the patho-
genesis of neurological disorders. Their genetic characterization and
the creation of transgenic mice developing human-like phenotypes
of neuropathologies and neurodegeneration have greatly contributed
in the effort for revealing the biochemical mechanisms of disease de-
velopment and progression. We have now reached the moment when
diagnostic tools are required to be reliable, applicable in a non-
invasive way and to make a bridge between the clinical application
and basic research. 1H NMR spectroscopy is a potentially valuable, if
not the best candidate to fulﬁll this role, since it allows monitoring
brain neurochemistry in humans and animal models of neurological
disorders in a non-invasive way, thus applicable longitudinally to
monitor degeneration during disease progression or recession upon
effective therapeutic intervention. Since exactly the samemethodolo-
gy can be applied to the human and to laboratory animals, it can be5.5 5.0 4.0 3.0
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Fig. 1. Compounds detected in the brain with in vivo 1H NMR spectroscopy. Sptranslated to the clinical routine. However, 1H NMR spectroscopy of
the rodent brain is technically challenging. These challenges of spec-
troscopy in rodents and particularly in mice had to be overcome to
obtain reliable and quantiﬁable data. The small size of the animal's
head implies that the region of interest for the NMR measurement
is typically close to the interface between the diamagnetic tissue
and the paramagnetic oxygen in air, thus inducing strong B0 inhomo-
geneity. Efﬁcient minimization of B0 inhomogeneity (shimming) is
required to achieve increased spectral resolution. Macroscopic sus-
ceptibility effects in different regions of the rodent brain can be elim-
inated with the use of contemporary shim coil designs for high order
shimming. The inherently small size of the region of interest is further
reduced when one aims to localize the spectra not only within the
brain but to functionally different cerebral areas, thus reducing sensi-
tivity that is the main intrinsic challenge of NMR spectroscopy. Sensi-
tivity can, however, be optimized using for example quadrature
surface coils for signal reception rather than using a transceiver2.0 1.0
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small ﬁlling factor of the rodent brain. In addition, high magnetic
ﬁelds and short echo times in carefully designed pulse sequences sub-
stantially improve sensitivity, as will be discussed bellow.
For a long time, 1H NMR spectroscopy in vivo was performed with
rather long echo times, simplifying the spectral analysis at lowmagnetic
ﬁelds but allowing quantiﬁcation of only few metabolites. Increases in
sensitivity and spectral resolution at high magnetic ﬁelds provides an
opportunity of quantifying at least 18 metabolites (Fig. 1) in the rodent
brain at ultra-short echo time (Pfeuffer et al., 1999). Since then, in vivo
1H NMR spectroscopy has been routinely used in preclinical and clinical
research as well as continuously improved.
The present review article covers, ﬁrst the technological aspects of
NMR spectroscopy aiming at the acquisition of 1H NMR spectra with
sufﬁcient quality for reliable quantiﬁcation of an extended neuro-
chemical proﬁle. A second part of the review describes the relevance
of the quantiﬁed metabolites for brain function. At last, disease appli-
cations of 1H NMR spectroscopy and future directions are discussed.
In general, previous articles aiming at reviewing the in vivo usage
of NMR spectroscopy for metabolite quantiﬁcation described possi-
ble or plausible functions for the normally observed metabolites. Be-
cause each detected molecule is involved in different metabolic
pathways and speciﬁc cerebral functions, in the present review we
suggest that the inverse approach, i.e. a discussion of metabolites in-
volved in each speciﬁc cellular role, should be preferred when prob-
ing the neurochemical proﬁle. Therefore, for different functional
aspects of the brain, the roles of different molecules are described
and discussed within the metabolic network and not as isolated che-
micals in test-tube environment.Instrumentation for MR spectroscopyTo perform in vivo 1HMR studies, amagnet, three orthogonalmagnet-
ic ﬁeld gradients, a set of shim gradients, transmit/receive RF coils or a
transceiver one, anRF ampliﬁer, a transmit–receive switch, a preampliﬁer,
a receiver (including analog–digital-convertors, ADC) and an interfaced
console allowing the control of all hardware components are necessary.
A full review of NMR instrumentation is beyond the scope of this review,
see (e.g. de Graaf, 2008). MR detectable signals are induced by a train of
radiofrequency (RF) pulses applied with or without gradients, received,
ampliﬁed and saved for further analysis.
Before MRI was introduced, NMR spectroscopy (MRS) had been
widely used in chemistry or physics. Thereafter, MRS, especially 1H
MRS, became an alternative means for in vivo studying brain function
and diseases of human and animals. With increased strength and sta-
bility of magnets and availability of contemporary techniques, quality
of in vivo 1H NMR spectra has been markedly improved.
Strengths of magnets
The sensitivity of the MR measurement is enhanced by increasing
magnetic ﬁeld strength, i.e. SNR or (Signal/σN) ∝B0β (Hoult and
Richards, 1976). When signal (S) theoretically increases with B02 and
achievable sensitivity is exclusively due to an increase in B0, β should
be no more than 2. Taking into account only electric components and
the RF coils as the dominant source of noise (Ne), its root-mean-
square amplitude may increase with the square root of frequency
(B0). Consequently, the standard deviation of the random noise, σN,
is the fourth root of B0. This leads to a generally accepted β=1.75.
However, for in vivo spectroscopy, the sample becomes one major
source of noise (Ns), which increases with B02. Thus the increased sen-
sitivity with B0 is close to linearity, β~1. Since the total noise is a com-
bination of both components, i.e. σN ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
σ2Ne þ σ2Ns
 
=2
q
(when
including both electrical and sample sources of noise), in vivo β isin the range of 1 to 1.75. Besides the noise, linewidths and relaxa-
tion times can inﬂuence sensitivity. At high magnetic ﬁeld, not
only magnetic susceptibilities but also longitudinal relaxation
times increase. Recent studies at high magnet ﬁelds (i.e. above
9.4 T) reported T1 of metabolites increased modestly (Cudalbu
et al., 2009; de Graaf et al., 2006). Therefore, the sensitivity decrease
due to an increase of T1 is not substantial. In contrast, the T2* de-
crease markedly affects peak heights due to ampliﬁed susceptibility
effects and reduction of transverse relaxation times (T2) will dimin-
ish the sensitivity when measured at long echo times (Mekle et al.,
2009; Tkáč et al., 2009).
Thus, the acquisition time at higher magnetic ﬁelds necessary for
achieving a required SNR is shorter than those at lower ﬁelds. Shorter ac-
quisitions allow functionalMRS (fMRS) studies in both human (Mangia et
al., 2007) and rodent brain (Xu et al., 2005). Additionally, spectral resolu-
tion is ampliﬁed with increased B0. This considerably improves informa-
tion content of 1H MRS by reducing signal overlap, typically observed at
lower magnetic ﬁelds (Mekle et al., 2009; Mlynárik et al., 2008a; Tkáč et
al., 2009). With such advantages of high magnetic ﬁelds, studying the re-
gional neurochemical proﬁle in small volumes of mouse brain after vari-
ous forms of intervention is feasible (Berthet et al., 2009, 2011; Lei et al.,
2009).
Gradient performance
Non-invasive localization of theMR signal in the brain cannot be done
without a magnetic ﬁeld gradient system. The gradient system allows
adding a magnetic ﬁeld increasing or decreasing linearly along any of
the threemain axes of the coordinate system (G,mT/m). Then, the result-
ing magnetic ﬁeld at a position r is B(r)=B0+rG. As a result, the reso-
nance frequency becomes dependent on position r, ω(r)=γB0+γrG.
The performance of gradients is crucial for the quality of localized
spectroscopy.
When the gradients are switched on and off, eddy currents are in-
duced in conductors in the vicinity of gradient coils, which may po-
tentially distort signals and induce localization errors that cause
artifacts in both images and spectra. Active shielding of gradients
reduces eddy currents substantially (Bowtell and Mansﬁeld, 1991;
Mansﬁeld and Chapman, 1986; Turner et al., 1988) and in combina-
tion with effective compensation methods (Boesch et al., 1991;
Jehensen et al., 1990; Kickler et al., 2010; Terpstra et al., 1998a; Van
Vaals and Bergman, 1990) the eddy current effects can be minimized.
RF considerations
It is desirable to have a homogenous RF ﬁeld covering the entire vol-
ume of interest (VOI) for bothMR imaging and spectroscopy. In general,
brain imaging is usually performed with volume RF coils, which are
available for conventionalMR scanners and provide sufﬁciently homog-
enous RF ﬁelds. However, when compared to the surface coils, volume
coils require increased RF power owing to large volume coverage
(Hoult and Richards, 1976). Conversely, increased power indicates di-
minished sensitivity based on the reciprocity principle. A potential
risk of the increased power to an MR examination is that the RF energy
is absorbed by the tissue and then converted to heat. Thus, the rate of
energy absorption, the speciﬁc absorption rate (SAR),must be restricted
in humans. With increased B0, RF wavelengths are shortened and thus
the RF ﬁeld generated by a classic human volume transmit coil varies
over space (so-called “dielectric resonance”). Although these problems
can complicate imaging techniques at high magnetic ﬁelds, including
MR spectroscopic imaging, use of adiabatic RF pulses and other alterna-
tives offered intriguing ameliorations (Adriany et al., 2008; Avdievich
et al., 2010; Henning et al., 2008; Hetherington et al., 2010; Katscher
et al., 2003, 2005; Van de Moortele et al., 2005). On the other hand,
for localized 1HNMR spectroscopy, the RFﬁeld for the targeting volume
can be calibrated using typically the tissue water signal. Recent human
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coil, while SAR is not of concern (Boer et al., 2011; Oz and Tkáč, 2011; Oz
et al., 2006).However,when longRF trains are applied, such as broadband
RF pulses for outer volume suppression, these limits can be exceeded.
In rodents, SAR concerns donot apply. The brain only occupies a very
small portion of the head, thus the volume coil can be used as a trans-
mitter producing a fairly homogeneous RF ﬁeld. However, the MRS sig-
nal should be detected by a more sensitive surface coil. Alternatively,
surface coils can be used as transceivers along with optimal adiabatic
RF pulses, which can overcome problems arising from inhomogeneous
RF ﬁelds. Numbers of studies have shown excellent performance of sur-
face coils for NMR spectroscopy at high magnetic ﬁelds in rodent brain
(Lei et al., 2010a,b; Tkáč et al., 1999), even for chemical shift imaging
(Mlynárik et al., 2008a), as well as for high resolution EPI images with
a full brain coverage (Lei et al., 2008; van de Looij et al., 2011b).
Coils at low temperature, cryo-coils, may provide gains in sensitivity
by reducing the ohmic losses for both imaging (Ginefri et al., 2007; Kwok
and You, 2006; Ma et al., 2003; Wright et al., 2000) and spectroscopy
(Ratering et al., 2008). The SNR was doubled when comparing with the
same coils at room temperature. This approach is very effective when
the coil is themajor source for noise, at the cost of increased distance be-
tween the coil and the sample due to the thermal isolation layer. For
human subjects, as well as many rodent applications, the sample itself
likely is the dominating contributor of noise. Therefore, the improve-
ments due to using cryo-coils for these studies might be limited.
Field homogeneity
The sensitivity improvements achievable at high magnetic ﬁelds de-
scribed above would not be possible unless the high magnetic ﬁeld in
the measured region is homogeneous enough. Magnetic ﬁeld inhomoge-
neities can have a dramatic effect on the quality of spectral data. At high
magnetic ﬁelds, the elevated magnetic susceptibility effect results in an
even shorter T2*. Consequently, the natural linewidth of metabolites in-
creases. To create a homogeneous magnetic ﬁeld over the VOI for spec-
troscopy, several methods have been proposed to improve ﬁeld
homogeneity by adjusting the corresponding coils (shim coils), which
are controlled by passing electric currents to create gradients of various
shapes. Before applying any adjustments,mapping themagnetic ﬁeld dis-
tribution is necessary, using a 3D gradient echomapping or a series of 2D
projection (Gruetter, 1993; Gruetter and Tkáč, 2000).
The ﬁrst- and second-order shims available for both experimental
andmany clinical magnet settings typically are sufﬁcient to obtain satis-
factory ﬁeld homogeneity over the VOI, including those in mouse brain
where magnetic susceptibility artifacts are ampliﬁed at high magnetic
ﬁelds (Lei et al., 2010b; Tkác et al., 2004, 2007). Therefore, automatic ad-
justments of these shim terms or even higher-order shim terms
(Gruetter, 1993; Gruetter and Boesch, 1992; Gruetter and Tkáč, 2000;
Hetherington et al., 2006; Miyasaka et al., 2006; Schneider and Glover,
1991; Shen et al., 1999; Zhang et al., 2009) are necessary for studying
the most common VOI in the rodent brain.
In vivo 1H NMR spectroscopy of the brain
Methods for 1H MRS localization
The full chemical shift range of most biologically interesting pro-
ton resonances is approximately within a range of 4 ppm, which
must be excited and acquired. In addition, endogenous water oc-
cupies nearly 80% of brain tissue. Thus, the water signal is several or-
ders of magnitude stronger than that of metabolites. In addition,
signals from extra-cerebral tissue, i.e. subcutaneous lipid can cause
artifacts and thus obscure cerebral signals. Therefore, adequate local-
ization of 1H signals is a prerequisite to acquire metabolites from the
target VOI with minimal non-cerebral and water signals.In the following, we provide a brief account of some techniques
used for 1H MRS of brain.
Image Selected In vivo Spectroscopy (ISIS)
Ordidge et al. (1986) described a full 3D localization with eight
scans, including a non-selective excitation and three frequency
slice-selective inversion pulses applied in the presence of three or-
thogonal gradients. For 1D ISIS, two scans, with and without one spa-
tial selective inversion pulse are required to localize this particular
slice. Due to the immediate acquisition of signal after excitation, ISIS
can be used to acquire metabolites with relatively short T2.
ISIS–90∘–acquisition½   8
In order to achieve a 3D volume localization, 8 scans must be ac-
quired with proper combination of slice-selective inversion pulses
on or off. Therefore, ISIS remains sensitive to subtraction errors due
to motion. When using a surface coil to achieve higher sensitivity,
this subtraction error can be reduced, whereas effects of B1 inhomo-
geneity can be minimized by using adiabatic pulses for selective in-
version (AFP) and excitation (adiabatic-half-passage (AHP) or BIR-
4(Garwood and Ke, 1991) pulses).
Point Resolved Spectroscopy (PRESS)
PRESS is based on a slice selective excitation, which is followed by
two frequency selective-refocusing pulses, a so-called double spin
echo method (Bottomly, 1984, 1987). Immediately after 90° and the
ﬁrst 180° pulses, the ﬁrst echo contains signals from an intersection
of two orthogonal slices deﬁned by these two slice-selective pulses.
With applying the second 180° pulse, the second spin echo contains
only signals from the deﬁned 3D volume. With such scheme, the sig-
nals outside the VOI are either not excited or defocused (spoiled).
90∘–t1–180∘–t1 þt2–180∘–t2–acquisition;
where
2  t1þ 2  t2 ¼ TE:
Adiabatic refocusing pulses have good slice proﬁles but they must be
used in pairs. A pair of hyperbolic secant type pulses can provide better
slice proﬁle than a classical (e.g. sinc-shaped) refocusing pulse, however,
they increase echo time (see also the LASER technique below).
Stimulated Echo Acquisition Mode (STEAM) spectroscopy
STEAM allows localizing the VOI with one single acquisition. This
technique is based on Hahn echoes (Hahn, 1950) by using three 90° fre-
quency selective RF pulses in the presence of magnetic ﬁeld gradients.
90∘−TE=2−90∘−TM−90∘−TE=2−acquisition
The method requires either crusher gradients in the TM period and
in both TE/2 periods to eliminate unwanted spin echoes and FIDs.
Along with the improved gradient performance and asymmetric RF
pulses, 1H MRS can be obtained at a 1 ms echo time (Tkáč et al.,
1999). However, compared to PRESS, half of signal is lost since the sec-
ond RF pulse only rotates half of the magnetization while the other half
is dephased by the crusher gradients.
Outer volume saturation (OVS) is widely used to eliminate
unwanted but incompletely suppressed signals such as the strong
extra-cerebral lipid signals from outside of the VOI, particularly in
ultra-short echo time spectroscopy when asymmetric pulses were ap-
plied (Mlynárik et al., 2006; Tkáč et al., 1999). This is because that de-
spite only about 25% of the asymmetric RF pulse duration time
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gradients, frequencies outside the nominal bandwidth of these asym-
metric pulses do not tend to cancel out as those from sinc pulses (Tkáč
et al., 1999). The localized 1H MRS methods using asymmetric pulses
did present contaminations from outside the VOI (Boer et al., 2011;
Oz and Tkáč, 2011), which can be eliminated with the optimized
OVS (Mlynárik et al., 2006; Tkáč et al., 1999; Oz and Tkáč, 2011).
Localization by Adiabatic Selective Refocusing (LASER) spectroscopy
A single-scan 3D localization uses adiabatic excitation and refo-
cusing RF pulses (Garwood and DelaBarre, 2001). Three pairs of
adiabatic-full-passage (AFP) RF pulses are used for generating multi-
ple spin echo and deﬁning a 3D volume.
AHP– AFP−AFP½   3–acquisition
With an increasing magnetic ﬁeld, increased spectral bandwidth
requires intrinsically higher RF power to achieve the identical band-
widths, which will limit its application in MR measurements within
SAR limits. Recently, an asymmetric slice-selective RF pulse has been
used for frequency selective excitation. In consequence, the numbers
of AFP pulses were reduced to two pairs, so called semi-LASER (Boer
et al., 2011; Oz and Tkáč, 2011). This particular pulse sequence allows
echo time to be shortened. Nevertheless, extra efforts, such as OVS and
adjusting dephasing gradients are necessary for the elimination of sig-
nals from outside the VOI (also necessary for PRESS).
SPin ECho full Intensity Acquired Localized (SPECIAL) spectroscopy
The SPECIAL sequence is a combination of 1D ISIS in one direction
followed by a slice-selective spin-echo in the other two orthogonal ori-
entations (Mlynárik et al., 2006).
1D−ISISY–90∘–180∘–acquisition
In combination with the adiabatic 180° slice selection (in ISIS),
this sequence employs two additional asymmetric pulses to achieve
a ﬁnal 3D deﬁnition with the echo time (Boer et al., 2011; Mekle
et al., 2009; Mlynárik et al., 2006) similar to that in STEAM (Tkáč
et al., 1999).Fig. 2. Spectroscopic imaging of the mouse brain after focal ischemia provides high-resolutio
for spectroscopic imaging acquisition. Upper row: T2-weighted coronal images at 24 h after
can be seen in the affected region on the right hemisphere. Bottom: Overlay of the correspon
[3] and hypothalamus [4]. Panels B and C show metabolite maps overlayed on the correspon
resent the VOI as shown in panel A. Typical spatial patterns can be observed in the contra
striatal taurine, also GABA concentration is high in the hypothalamus.
Figure was reproduced from Alf et al., 2011 with authorization of the publisher.Since a 1D ISIS component is included for localization scheme, at
least two scans are required for localization of the third dimension,
which makes this sequence sensitive to motion. However, in combi-
nation with efﬁcient OVS, a substantial number of studies in human
and rodent brains showed similar spectral quality as that of STEAM
at short echo time but with doubled sensitivity (e.g. Duarte et al.,
2009a; Kulak et al., 2010; Lei et al., 2009, 2010a,b; Mekle et al.,
2009; Mlynárik et al., 2006, 2008a).
Short echo time localization pulse sequences are desirable to maxi-
mize the information in the 1H NMR spectra (Pfeuffer et al., 1999). The
use of short TE allows tominimize J-modulation of coupled spin systems,
which form themajority ofMRdetectable cerebralmetabolites, and to re-
duce signal losses caused by T2 relaxation. T2 relaxation times are signiﬁ-
cantly shorter at highmagnetic ﬁelds (Xin et al., 2008) and are difﬁcult to
quantify for coupled spin systems in vivo. In addition, a long repetition
time (TR) allows eliminating effects of unknown T1 relaxation times.
Water suppression
Water occupies approximately 80% of the total weight of brain tissue
and represents the most abundant signal in proton MRS at ~4.7 ppm.
This leads among others to a distorted baseline and spurious signals,
which in turn make the detection of metabolites unreliable. Therefore,
elimination of water signal improves the reliability of in vivo spectra
quantiﬁcation.
In general, suppression of a particular resonance in NMR requires a
difference in a property between compounds of interest and the interfer-
ing compound. Several suppression methods are available, such as fre-
quency selective and/or defocusing, exploiting different relaxation
properties, spectral editing and others. Sincewater has a unique chemical
shift apart frommostmetabolites, water suppression for short echo time
1H MRS mostly relies on frequency-selective pulses. Seven such pulses
(VAPOR) with optimal ﬂip angle and timing allows for efﬁcient water
suppression in in vivo brain studies (Mlynárik et al., 2006; Tkáč et al.,
1999; Oz and Tkáč, 2011), in spite of variations in the RF ﬁeld amplitude
and T1 of water.
Chemical shift displacement error
All localization methods described above are based on applying a
RF pulse in the presence of a gradient. For this reason, with frequency
difference (Δω), localization is shifted by Δx ¼ ΔωγGx, where Gx is then spatial mapping of neurochemical changes. Panel A depicts the position of the volume
transient ischemia contributing to the spectroscopic imaging signal. Intensity changes
ding NAA map and indication of the ischemic core [1], penumbra [2], cortical penumbra
ding anatomical images after 3 h (B) and 24 h (C), color scale in μmol/g. The maps rep-
lateral hemisphere, i.e. on the left hand side, such as high cortical glutamate and high
347J.M.N. Duarte et al. / NeuroImage 61 (2012) 342–362slice-selective gradient strength and γ is the gyromagnetic ratio. This
effect is called chemical shift displacement error. For example, given
Gx=400 mT/m and 5 ppm chemical shift range for proton
(γ=42 MHz/T) at 400 MHz, the maximum displacement errors,
2.5 ppm away from the transmitter offset, are not more than
0.06 mm.With increased ﬁeld strengths, spectral dispersion increases
and so does the chemical shift displacement error.Spectroscopic imaging
On the other hand, while the localization techniques described
above allow signal detection from a well-deﬁned volume, spectro-
scopic imaging, also called chemical shift imaging (CSI), allows the
detection of multiple spectra (e.g. Brown et al., 1982). However,
these multivoxel NMR spectroscopy methods are intrinsically affect-
ed by inhomogeneity across the large measured volume and require
long data acquisition times. Nonetheless, spectroscopic imaging can
be performed in rodents with μL spatial resolution, which is compara-
ble to other imaging modalities, for example animal positron emis-
sion tomography (PET). A neurochemical proﬁle of more than 10
metabolites at short echo-time in the rat brain has thus been imaged
at 9.4 T (Mlynárik et al., 2006, 2008b; Weiss et al., 2009).
Spectroscopic imaging is particularly useful in the diagnosis of is-
chemic injuries (Fig. 2), being capable to identify the neurochemical
proﬁle in the infarct region, edematous tissue, penumbra and healthy
unlesioned tissue (e.g. Alf et al., 2011; Cvoro et al., 2009; Mlynárik
et al., 2008a). Similarly, the study of cerebral tumors beneﬁts from
the possibility of detecting different metabolic states (edema, necro-
sis, neoplastic cells) in the lesion (e.g. Löbel et al., 2011; Server
et al., 2010; Simões et al., 2010).Table 1
Neurochemical proﬁle detected in the cerebral cortex of adult C57BL/6 mice at 14.1 T
(from Kulak et al., 2010; Duarte et al., 2011), Sprague–Dawley rats at 9.4 T (from Lei
et al., 2009; Xin et al., 2010a) and humans at 3.0, 7.0 T (from Gambarota et al., 2009;
Mekle et al., 2009) and at 9.4 T (Deelchand et al., 2010).
Mouse
cortex
Rat
cortex
Human occipital
cortex
Alanine 0.9–1.2 0.4–0.6 0.3a
Aspartate 1.8–2.3 1.9–2.6 2.1–3.1
Phosphorylcholine (PCho) 0.5–0.6 0.4–0.5 –
Creatineb 3.9–4.5 2.7–3.8 3.2–5.8
Phosphocreatineb 3.6–4.3 3.8–5.2 2.2–4.5
γ-aminobutyrate (GABA) 1.7–2.0 1.1–1.4 1.3–2.5
Glutamine 3.6–3.9 3.5–4.3 1.6–2.2
Glutamate 10.3–11.2 10.3–12.9 8.9–12.8
Glutathione 1.2–1.4 0.7–1.2 1.1–1.4
Glycine 0.9–1.5 0.6–0.9 1.2c
myo-inositol 4.4–4.8 3.8–4.5 4.9–5.7
Lactateb 1.6–2.1 0.4–1.6 0.5–0.7
N-acetylaspartate 8.7–9.7 8.6–10.5 11.0–13.5
scyllo-inositol 0.2d 0.1–0.2 0.3–0.4
Taurine 8.9–11.0 5.0–6.9 1.3–3.3
Ascorbate 1.2–2.1 1.0–1.6 1.4d
Glucoseb 1.6–2.0 2.2–4.1 1.4–2.24
N-acetylaspartylglutamate
(NAAG)
0.6–0.9 0.3–0.7 1.0–1.1
Glycerylphosphorylcholine
(GPC)
0.5–0.8 0.1–0.2 –
Phosphorylethanolamine 1.7–1.9 1.8–2.1 1.6–2.8
β-hydroxybutyrateb – 0.5–1.3 –
GPC+PChoe 1.0–1.2 0.5–0.8 0.9–1.1
a Only reported by Deelchand et al. (2010).
b Dependent on nutritional state and anesthesia.
c Only reported by Gambarota et al. (2009).
d Only reported by Kulak et al. (2010).
e Often the concentration of each choline metabolite is not reported and therefore
total concentration of choline-containing metabolites is given.Quantiﬁcation of in vivo 1H NMR spectra
The NMR signal acquired with localized 1HMRSmethods is, in prin-
ciple, proportional to the induced transverse magnetization of spins
originating from the targeting volume. Despite the sample itself, instru-
mental factors and anMRpulse sequence can inﬂuence the direct calcu-
lation of the corresponding metabolite concentration. By using
validated reference methods, MRS signals can be quantiﬁed to provide
biochemical information.
There are two main approaches for non-invasive quantiﬁcation,
i.e. internal and external reference methods. The internal referentia-
tion is generally made by normalization of the signals to a known
(assumed constant) concentration. Frequently, total creatine is used
as a reference for the remaining metabolite concentrations. However,
its concentration (signal) may change in pathological conditions
(Duarte et al., 2009a,c, 2011), with age (Kulak et al., 2010) and
between gray and white mater (Mukherjee et al., 2000). Therefore,
most often a non-water-suppressed spectrum is acquired under the
same experimental conditions. From the water content, concentration
is calculated. Attention should be given to the fact that water content
changes when pathologies lead to reduction of brain mass and
ventricle enlargement or in the case of edema, and varies with age
(e.g. Kulak et al., 2010; Tkáč et al., 2003 and references therein).
The external referencemethod applies the identical settings of an in
vivo experiment on an in vitro solution containingmetabolites of known
concentrations. This method is suitable for metabolites having known
or similar relativity properties between in vivo and in vitro, and present-
ing less complicated spectral patterns while high spectral resolution is
offered, for example in 13C MRS (e.g. see review Gruetter et al., 2003)
and with spectral editing (Terpstra et al., 2002). The peak areas can be
quantiﬁed by numerical integration for visible and prominent metabo-
lite resonances.
The 1H MR spectral pattern is complex and severely overlapped.
Although with increased magnetic ﬁeld strength these problems
are reduced, signal overlap remains. Therefore, methods allowing14.1 T
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Fig. 3. Localized 1H NMR spectra acquired with SPECIAL spectroscopy at different mag-
netic ﬁelds. Spectra at 3.0 and 7.0 T were acquired from cortical regions of the human.
Spectra at 9.4 and 14.1 T are from the hippocampus of the rat and mouse, respectively.
Metabolites in the spectra are assigned as follows: myo-inositol (Ins), phosphocreatine
(PCr), creatine (Cr), glutamate (Glu), glutamine (Gln), taurine (Tau), glycerophosphor-
ylcholine (GPC) phosphorylcholine (PCho), γ-aminobutyrate (GABA), aspartate (Asp), N-
acetylaspartate (NAA), N-acetylaspartylglutamate (NAAG), alanine (Ala), lactate (Lac).
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Fig. 4. Regional speciﬁcity of 1H NMR spectroscopy of the brain. Spectra were acquired from the mouse brain at 14.1 T using SPECIAL.
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several approaches available that use prior knowledge, such as
VARPRO, AMARES, LCModel and others (Abildgaard et al., 1988; de
Graaf and Bovee, 1990; Naressi et al., 2001; Provencher, 1993;
Slotboom et al., 1998; Van der Veen et al., 1988; Vanhamme et al.,
1997). For 1H MRS, LCModel adjusts the amplitudes, line widths and
phases of the metabolite basis set to match the in vivo and in vitro
spectra as close as possible (de Graaf et al., 2011; Pfeuffer et al.,
1999; Provencher, 1993).
The neurochemical proﬁle detected by 1H NMR spectroscopy
Metabolite concentrations often reﬂect the activity of metabolic
processes. At high magnetic ﬁeld, nowadays considered 7 T and
above, a neurochemical proﬁle of more than 20 metabolites can be
determined in a non-invasive way under normal physiological condi-
tions (Fig. 1). As general rule, 1H NMR spectroscopy can detect all
compounds existing in a concentration above 0.5 μmol/g.
The concentrations of most brain metabolites within the neuro-
chemical proﬁle are modiﬁed during development reﬂecting the
structural and functional evolution inherent to the differentiation of
cerebral networks (e.g. Kulak et al., 2010; Tkáč et al., 2003). The neu-
rochemical proﬁle is region speciﬁc (Kulak et al., 2010; Lei et al.,
2010b; Tkáč et al., 2003, 2004; Xin et al., 2010a), reﬂects functional
states (Mangia et al., 2007) and is affected by pathological conditions
(e.g. Duarte et al., 2009a, 2011; Lei et al., 2009; Tkáč et al., 2007; van
de Looij et al., 2011a,b). Therefore, the non-invasively detected neu-
rochemical proﬁle may be taken as a marker for speciﬁc metabolic
states that are associated with degeneration or acute injury as is dis-
cussed in the present review. In addition, for a given brain area, the
neurochemical proﬁle is species dependent (see Table 1) and it mayeven vary within different strains of the same species (Tkáč et al.,
2004). As such, although brain metabolism has wide differences
among species namely when comparing rodents to humans, once
the role of the measured neurochemicals is understood, high resolu-
tion NMR qualiﬁes as method of choice for in vivo translational inves-
tigations of preclinical animal models of human neurological and
psychiatric pathologies during development or aging.
For example, the metabolites composing the neurochemical pro-
ﬁle detected by non-invasive 1H NMR spectroscopy in the adult cor-
tex are depicted in Table 1, for mice, rats and humans. Spectral
quality from 3 to 14.1 T and regional differences in spectral paters
can be appreciated in Figs. 3 and 4, respectively.
Neurotransmitter metabolism
Amino acid neurotransmitters are the most abundant transmitters
in the central nervous system playing an important role in the wiring
of neuronal networks and organizing cyto-architecture during cere-
bral development and differentiation. Their concentrations are
strongly altered if the neuronal network is disrupted upon injury.
Glutamate and aspartate are the dominant excitatory amino acids.
The concentrations of both increase steadily during early develop-
ment until adulthood, as measured in vivo in rats (Tkáč et al., 2003)
and mice (Kulak et al., 2010). The fast early concentration rise espe-
cially of glutamate closely parallels the time course of glutamatergic
synaptogenesis andmarks a period of ongoing reﬁnement of the cere-
bral circuitry. As glutamatergic synapses develop and mature, energy
demand rises. Thus, this early period is also associated with a major
step in the maturation of energy metabolism, demonstrated by the
concomitant modiﬁcation in the brain levels of glucose and lactate
(discussed below).
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of reducing equivalents produced in the glycolysis from the cytosol
into the mitochondrial matrix through the malate–aspartate shuttle,
a major step in neuroenergetics (Gruetter et al., 2003; McKenna,
2007). Therefore, these two amino acids are used in processes that
may link excitatory neurotransmission to energy production and
usage.
Glutamine is synthesized from glutamate by glutamine synthetase
in glia and converted back to glutamate by glutaminase in neurons,
completing the glutamate–glutamine cycle. This cycle is not stoichio-
metric (McKenna, 2007) and both glutamate and glutamine are en-
gaged in a number of important metabolic pathways like energy
provision, synthesis of important chemicals like N-acetylaspartate
(NAA), N-acetylaspartylglutamate (NAAG), γ-aminobutyrate (GABA)
and glutathione (GSH), and protein synthesis. Thus, it is expected
that glutamate and glutamine concentrations develop similarly as
both are functionally coupled through this glutamate–glutamine
cycle (for review see e.g. Zwingmann and Butterworth, 2005).
Glutamine is synthesized and mainly present in the glia. Its con-
centrations rise within the ﬁrst weeks of life in the rat (Tkáč et al.,
2003) and mouse (Kulak et al., 2010) brain, similarly to those of
glutamate, reﬂecting the maturation of the glio-vascular unit that
supports neuronal function. Glutamine synthesis is also used for am-
monia detoxiﬁcation (Cudalbu et al., 2011) and has been shown to be
a good marker of hepatic encephalopathy (Behar et al., 1999; Córdoba
et al., 2002; Kreis et al., 1991).
For a long time, non-invasive detection of a peak corresponding
mainly to resonances of glutamate and glutamine in cerebral tissue
has been taken as a marker of function and degeneration in pre-
clinical and clinical studies. Only the advances of the last decade and
the increase inmagnetic ﬁeld strength allowed independent quantiﬁca-
tion of both glutamate and glutamine. An independentmeasure of both
and also their ratio may be a better marker to indicate neuronal func-
tion, as glutamate and glutamine are mostly located in neurons and
glia, respectively. For example, impaired neurotransmission and excito-
toxicity after an ischemic insult lead to transient glutamate decrease
and glutamine accumulation (Berthet et al., 2011; Lei et al., 2009). In
line with this idea, disturbed glutamatergic neurotransmission in ante-
rior regions of the schizophrenic brain leads to altered levels of gluta-
mine, glutamate and most notably of glutamine to glutamate ratio, as
observed in clinical 1H NMR spectroscopy studies (Bustillo et al., 2009;
Lutkenhoff et al., 2008; Shirayama et al., 2010; Tayoshi et al., 2009).
Glutamate can be decarboxylated to GABA for use in GABAergic neu-
rotransmission. A signiﬁcant pool of brain glutamate is involved in this
process (discussed in Hertz, 2006). Although GABA concentrations re-
main stable throughout development (Kulak et al., 2010; Tkáč et al.,
2003), modiﬁcations in metabolic and signaling fates of GABA occur at
the time of GABAergic inhibitory synapse formation (Anderson et al.,
1995) and with the increment of cortical GABA binding sites (Skerritt
and Johnston, 1982). At low magnetic ﬁelds, GABA is difﬁcult to mea-
sure in 1H NMR spectra and its detection has been achieved by editing
techniques, which are not exempt of quantiﬁcation errors (Bielicki
et al., 2004; Choi et al., 2005; Mescher et al., 1998; Terpstra et al.,
2002). Higher magnetic ﬁelds, on the other hand, provide increased
spectral resolution making GABA quantiﬁable (Deelchand et al., 2010;
Gambarota et al., 2009; Mekle et al., 2009; Oz et al., 2006). GABA con-
centrations were found to be affected by neurological disorders like ep-
ilepsy (Doelken et al., 2010; Goddard et al., 2001; Simister et al., 2003),
schizophrenia (Yoon et al., 2010), depression (Sanacora et al., 2004) or
substance abuse (Behar et al., 1999; Ke et al., 2004).
NAAG is a highly abundant neuromodulatory peptide in the brain
that is expressed in neuronal terminals (Shave et al., 2001) and to lesser
extent in glial cells (Cassidy andNeale, 1993). It is synthesized fromNAA
under tight regulation and acts on presynaptic metabotropic glutamate
receptorsmGluR2/3 to down-regulate neurotransmitter release via neg-
ative feedback (Zhao et al., 2001) and onN-methyl-D-aspartate (NMDA)receptors either as direct agonist (e.g. Westbrook et al., 1986) or antag-
onist (e.g. Burlina et al., 1994). NAAG levels detected in vivo in the
mouse brain are highest after birth and decline thereafter to reach a sta-
ble plateau at adult age (Kulak et al., 2010). This exactlymimics early re-
sults obtained with tissue extracts (Koller and Coyle, 1984).
Glycine has a dual role as inhibitory neurotransmitter, on one
hand activating glycine receptors, and on the other as co-agonist for
glutamate excitatory transmission through NMDA receptors (Betz
and Laube, 2006). The proton resonances of glycine are a singlet over-
lapping with a more intense resonance of myo-inositol. This singlet
was detected in the brain of both rodents (Gambarota et al., 2008;
Xin et al., 2010a) and humans (Gambarota et al., 2009). Glycine is
particularly highly concentrated in the brain stem, namely in medulla
oblongata (Xin et al., 2010a), where a large portion of synapses are in-
volved in glycinergic neurotransmission. Like for NAAG, the highest
glycine concentrations in the brain are observed at P10 and decline
until adulthood (Kulak et al., 2010). In fact, the rate of glycine synthe-
sis peaks around 10–15 days after birth (Benítez-Diaz et al., 2003;
Lahoya et al., 1980) and likewise, during this period, glycine receptors
undergo a major switch of the relative expression of glycinergic sub-
units (Lynch, 2004). It is interesting to note that the increase in levels
of excitatory neurotransmitters, glutamate and aspartate (NMDA re-
ceptor agonists), is paralleled by a reduction in the concentration of
its modulator NAAG as well as its co-agonist glycine.
Taurine is, among other functions, also a neuromodulator (Gupta
et al., 2009). Taurine released from neurons and glia interacts with in-
hibitory GABAA, GABAB or glycine receptors (reviewed in Albrecht and
Schousboe, 2005) thus displaying capability of modulating synaptic
plasticity (e.g. del Olmo et al., 2000). This inhibitory role of taurine is es-
pecially important during the period of cortical synaptogenesis (Flint
et al., 1998), when brain taurine levels are found to be highest (Kulak
et al., 2010; Tkáč et al., 2003). Like glycine andNAAG, taurine concentra-
tion in the brain decreased during development to adult age (Kulak
et al., 2010; Tkáč et al., 2003). However, as a small fraction of taurine
is involved in neuromodulation (particularly in the case of rodents),
themain role of taurinemay be rather related to osmoregulation, balan-
cing the increase in glutamate, glutamine, NAA and other neurochemi-
cals during development (Kulak et al., 2010) and counteracting
osmolarity imbalance upon brain injury (Berthet et al., 2011; Lei et al.,
2009). Interestingly, taurine concentrations in the human brain are rel-
atively low (Table 1) and the role in neuromodulationmay bemore im-
portant than in controlling cell volume and osmolarity.
Cellular proliferation and membrane lipid metabolism
N-acetylaspartate (NAA) is among the most abundant neurochemi-
cals, with concentrations on the order of 10 μmol/g in the human and
rodent brain (Table 1). NAA is generally taken as a putative neuronal
marker with its almost exclusive localization in neurons, turning it in
a reliable diagnostic marker. In fact, NAA levels are frequently found
to be absent in tumors of glial origin (e.g. Sibtain et al., 2007) and to de-
crease in neuropathological conditions, correlating with the degree of
degeneration in humans (Bruhn et al., 1989; Gideon et al., 1992, 1994;
Horská et al., 2009; Kantarci, 2007) and rodents (e.g. Berthet et al.,
2011; Lei et al., 2009; Tkáč et al., 2007). In addition, after transient ische-
mia and brain injury without neuronal death, NAA levels are able to re-
cover (Brulatout et al., 1996; De Stefano et al., 1995), suggesting it as a
marker of neuronal functionality rather than neuronal density.
Developmental increase of NAA content in cortical regions of the
rodent (Kulak et al., 2010; Tkáč et al., 2003) or human brain (Ross
and Blüml, 2001) may be associated with neuronal proliferation and
its role in lipid and myelin synthesis (Burri et al., 1991; D'Adamo
and Yatsu, 1966). Accordingly, axonal demyelination is associated
with reduction of NAA (Bitsch et al., 1999). Although NAA is mainly
synthesized and stored in neurons from mitochondrial acetyl-CoA
and aspartate (Baslow, 2003), its deacetylation occurs in
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replenish both acetyl-CoA and oxaloacetate (through aspartate) pools
providing carbon skeletons for both energy production and local lipid
synthesis, required in the myelination process. The signiﬁcant reduc-
tion in PE and increase in NAA concentrations in the cerebral cortex
from P20 onwards may reﬂect the rate of deposition of myelin that
is very rapid between P14 and P30 yet continues afterwards at slower
rate (Costantino-Ceccarini and Morell, 1972; Muse et al., 2001). In
line with this role of NAA, Canavans disease is characterized by accu-
mulation of NAA due to impaired deacetylation in olygodendrocytes,
which is associated to defects in myelin synthesis and deposition
(Chakraborty et al., 2001).
Inositol has several isomers, being myo-inositol (~4 μmol/g) the
main contributor to the peak observed in 1H NMR spectra of the
brain. The second most concentrated isomer is scyllo-inositol
(~0.2 μmol/g) that possesses six symmetric protons and originates a
singlet at 3.34 ppm. The increase of myo-inositol concentration during
development (Kulak et al., 2010; Tkáč et al., 2003) seems to be related
to the demand for synthesis of inositol-containing phospholipids dur-
ing synaptogenesis, axonal growth and myelination. Accordingly, Yao
et al. (1999) reported an increase of phosphatidylinositol that may be
incorporated into lipid membranes (Quarles et al., 2006) during
mouse brain development. In several neurological disorders, myo-
inositol was found to be increased (Bitsch et al., 1999; Horská et al.,
2009; Kantarci, 2007) and this is generally assumed to be a marker of
gliosis, based on the fact that higher myo-inositol levels are found in
cultured astrocytes as compared to neurons in vitro (Brand et al.,
1993; Glanville et al., 1989). However, brain myo-inositol levels may
not always correlate with other molecular markers of gliosis (Duarte
et al., 2009a; Kim et al., 2005; Kunz et al., 2011).
Choline-containing compounds are essential for membrane lipid
synthesis and act as precursors for the biosynthesis of the neurotrans-
mitter acetylcholine. The methyl protons of choline-containing com-
pounds all resonate at 3.2 ppm. In the brain, choline is below the
NMR detection limit and mainly glycerylphosphorylcholine (GPC)
and phosphorylcholine (PCho) contribute to this intense resonance
(e.g. Klein, 2000). At a high magnetic ﬁeld, namely 14.1 T, it was
possible to quantify the two phosphorylated compounds of choline
through the distinct multiplicity of their remaining resonances
(Kulak et al., 2010; Mlynárik et al., 2006).
Choline availability seems crucial for the onset of GABAergic neu-
ronal differentiation, especially during embryonic brain development
(Albright et al., 2003) and progenitor cell proliferation and apoptosis
in mouse brain (Craciunescu et al., 2003). Modiﬁcation of cerebral
choline concentration during development was found to be region
and species speciﬁc. In general, brain choline increases with age in
the mouse brain (Kulak et al., 2010) but not in rats (Tkáč et al.,
2003). In humans, using 31P NMR spectroscopy, it was found that
both phosphorylcholine and phosphorylethanolamine decrease dur-
ing development with concomitant increase in the glycerylated
forms of these phospholipids (Blüml et al., 1999).
Total choline concentration (including free choline and phosphory-
lated choline metabolites) in the human brain is positively correlated
with age (e.g. Angelie et al., 2001; Chang et al., 1996; Kreis et al.,
1993; Pfefferbaum et al., 1999a,b). This age-associated increase in cho-
line has been attributed to increased release of water-soluble choline-
containing compounds from cell membranes, reﬂecting higher
membrane turnover (Chang et al., 1996). In line with this, choline-
containing compounds are associated with high cellular proliferation
and inﬂammatory responses in tumor growth and, therefore, choline
is often taken as a marker for diagnosis of certain brain tumors (e.g.
Kinoshita and Yokota, 1997; Li et al., 2007; Sibtain et al., 2007).
Phosphorylethanolamine (PE) is a precursor for phosphatidyleth-
anolamine, which is a major phospholipid in the brain (Quarles et al.,
2006). Phosphorylethanolamine concentration decreases during ce-
rebral development and this observation is consistent in rodentsand humans, paralleling the progression of myelination and cellular
proliferation (Blüml et al., 1999; Gyulai et al., 1984; Kulak et al.,
2010; Tkáč et al., 2003; Turner et al., 1994; Rao et al., 2003; Wijnen
et al., 2010a). Like choline, increased PE metabolism during high
cellular proliferation was found in several types of brain tumors
and to correlate with tumor malignancy (e.g. Kinoshita and Yokota,
1997).
In general, for both rodents and humans, NAA concentration rises
during development while choline and ethanolamine are reduced
(Kulak et al., 2010; Ross and Bluml, 2001; Tkáč et al., 2003; Blüml
et al., 1999). In the human brain, the concentration of NAA was
found to be reduced upon aging (Chang et al., 1996; Gruber et al.,
2008; Schuff et al., 1999, 2001), while choline and myo-inositol in-
creased (Chang et al., 1996; Gruber et al., 2008). This suggests that
cell membrane constitution and turnover are modiﬁed during devel-
opment and aging, as is plasticity of neuronal circuits.
Energy metabolism
Depending on its physiological state and maturity, the brain uti-
lizes different energy substrates including glucose, ketone bodies
and lactate (e.g. Lust et al., 2003; Nehlig, 2004; Vannucci et al.,
1994). In the brain of suckling rodents, ketone bodies can represent
up to 70% of the total energy substrate pool (Nehlig, 2004). Rheims
et al. (2009) have shown that, during early postnatal development,
ketone body availability modulates GABA signaling and efﬁciently
controls the excitability of neonatal cortical neurons.
In the mouse brain, lactate concentrations were found to be rela-
tively unaltered during early development and increase at adult age
(Kulak et al., 2010). In developing rats, Tkáč et al. (2003) did not ob-
serve changes in lactate concentration during cortical development,
whereas Lust et al. (2003) found high lactate in neonate rats and a
strong decrease in adults. Lactate generated and released by astro-
cytes has been suggested to serve as an energy substrate for neurons,
especially during synaptic activity (Pellerin and Magistretti, 1994)
and during re-oxygenation after stroke (Berthet et al., 2009). Ascor-
bate may play a role in this process by regulating glucose transport
and glycolysis (Castro et al., 2009). Cerebral ascorbate concentration
decreases during development to adult age (Kulak et al., 2010;
Terpstra et al., 2010) therefore suggesting that ascorbate-induced
glucose transport inhibition and lactate transport stimulation may
be higher in early developmental stages than in adulthood. This cor-
roborates the preferential use of other substrates rather than glucose
by the developing brain (Lust et al., 2003).
Alanine is an amino acid with close links to metabolic pathways
such as glycolysis, tricarboxylic acid cycle and protein synthesis.
Like for lactate, with which it is in equilibrium though pyruvate, con-
ﬂicting observations were reported for alanine concentrations in the
developing rat brain (Bayer and McMurray, 1967; Burri et al., 1990;
Tkáč et al., 2003). However, both in vivo and in vitro studies in mice
demonstrated that cerebral alanine content is higher at birth and de-
creases during development (Kulak et al., 2010; Yao et al., 1999),
reﬂecting the high protein turnover in the developing brain as result
of cell proliferation and tissue expansion.
These events require availability of energy, typiﬁed in the larger
concentration of phosphocreatine relative to creatine at early devel-
opmental ages. Total creatine content was found to increase in the
cortex during development (Kulak et al., 2010), following the modiﬁ-
cation in brain creatine kinase activity (Manos et al., 1991), which is a
critical component in maintaining brain energy homeostasis by buff-
ering cellular energy demands.
More than buffering energy requirements, the creatine–
phosphocreatine equilibrium is thought to be amechanism for energy
transport from the mitochondrial producing site to the synaptic con-
sumption at the nerve terminals. Total creatine is more concentrated
in gray than white matter (e.g. Pouwels and Frahm, 1998), and thus
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creatine is often assumed to be constant but is frequently found to be al-
tered by acute brain injury and neurological disorders.
Othermetabolites related to energymetabolism are often included in
the neurochemical proﬁle but not observable in normal subjects by in
vivo 1H NMR spectroscopy. Acetate is taken up by the brain and metab-
olized in glial cells (Cerdan et al., 1990; Waniewski and Martin, 1998)
and is often used as tracer to probe astrocytic intermediary metabolism
upon infusion in the blood stream (e.g. Xin et al., 2010b). Recently,
Hong et al. (2011) claimed that the methyl protons of acetate can be
detected in 1H NMR spectra of the normal rat brain in vivo at 16.4 T. A
large concentration of pyruvate, the end product of glycolysis, was
detected in vivo in the brain of neonates with pyruvate dehydrogenase
deﬁciency (Zand et al., 2003). Both acetate and pyruvate, which exist in
undetectable concentrations, were detected at high levels in cystic le-
sions by in vivo 1H NMR spectroscopy (Jayakumar et al., 2003; Kohli et
al., 1995).
Metabolic disorders such as diabetes result in alterations of the
neurochemical proﬁle (Duarte et al., 2009a; Geissler et al., 2003;
Kreis and Ross, 1992; van der Graaf et al., 2004), regarding metabo-
lites involved in energy metabolism. Hyperglycemia increases brain
levels of glucose and β-hydroxybutyrate, is an indicator of ketoacido-
sis, and is quantiﬁable at a high magnetic ﬁeld (Duarte et al., 2009a;
Lei et al., 2010a). Increased lactate concentrations are very common
in certain acute insults or in brain disorders that affect mitochondrial
function and upregulate the glycolytic pathway (e.g. Lei et al., 2009;
van de Looij et al., 2011a).
Finally, it is very important to stress that the brain energy status de-
pends on neuronal activity and, therefore, on the type and deepness of
anesthesia used for the NMR study (Lei et al., 2010a). In addition, the nu-
tritional conditions may also induce speciﬁc neurochemical patterns, es-
pecially when studying brain energy metabolism.
Osmoregulation
Osmolarity alterations trigger physiological responses that involve
the balance of both ions (mainly sodium, potassium, and chloride) and
organic compounds, i.e. idiogenic osmolytes, since in principle everyme-
tabolite occurring at high concentration is a potential regulator of cellular
osmolarity. Osmolarity control in the brain is considered to occurmainly
but not exclusively via the concentrations of taurine, creatine and myo-
inositol. Hypoosmolarity induces their release while hyperosmolarity
causes their slow accumulation (see Verbalis, 2010 for review). Taurine
is known to have threemain roles in the brain, namely acting as a neuro-
modulator (discussed above), an antioxidant and an osmoregulator
(Albrecht and Schousboe, 2005; Gupta et al., 2009). Accordingly, its in-
tracellular content changes in parallel with plasma osmolarity
(Trachtman et al., 1992; Rose et al., 2000). Taurine is one of themost con-
centratedmetabolites in the rodent brain, decreasing from about 20 mM
at P10 to 10 mM in adult mice (Kulak et al., 2010; Weiss et al., 2009).
Similar observations were reported in the rat (Tkáč et al., 2003). On the
other hand, concentrations ofmyo-inositol and creatine increase during
development of the rodent cortex (Kulak et al., 2010; Tkáč et al., 2003),
balancing taurine reduction. Supporting their role in osmoregulation,
for example, chronic hyponatremia leads to reduction of taurine, crea-
tine, myo-inositol and also glutamate and glutamine (Verbalis, 2010).
Chronic hyperglycemia alters osmolarity homeostasis and likewise the
brain content of taurine, creatine and myo-inositol is increased (Duarte
et al., 2009a; van der Graaf et al., 2004). NAA can be released to the inter-
stitial space upon osmotic challenges (e.g. Sager et al., 1997; Bothwell et
al., 2001) suggesting that it may also play a role in osmorelulation.
Antioxidant defense
Neurological disorders are often associated with deﬁciency of an-
tioxidant protection systems (e.g. Ballatori et al., 2009; Do et al.,2009; Martin and Teismann, 2009). However, antioxidant compounds
generally exist in low concentration and non-invasive detection is
therefore challenging. Glutathione and ascorbate (vitamin C) are
two major antioxidants that can be detected by 1H NMR spectrosco-
py using e.g. selective editing techniques (e.g. An et al., 2009; Kaiser
et al., 2010; Terpstra and Gruetter, 2004; Terpstra et al., 2003). At a
high ﬁeld, with gain in sensitivity and spectral resolution, direct de-
tection of glutathione and ascorbate at short echo time is possible
(e.g. Terpstra et al., 2005, 2006).
While ascorbate is predominantly in the neuronal compartment
(Rice, 2000), glutathione is more concentrated in glia than neurons
(Dringen, 2000), both existing under tight homeostatic regulation
by synthesis and/or transport through the blood–brain-barrier. Gluta-
thione acts in concert with ascorbate that is also an enzyme co-factor
in the brain and is involved in maintenance of brain homeosthasis. As
such, ascorbate is involved in antioxidant protection and regulation of
glucose metabolism (Castro et al., 2009), but not exclusively. It also
plays a role in myelin formation (Eldridge et al., 1987), enhancement
of synaptic activity (Rebec and Pierce, 1994) and direct protection
from excitotoxicity (Qiu et al., 2007). In vivo 1H NMR spectroscopy
revealed high ascorbate concentrations in young (P10) animals and
a subsequent steady decline until adulthood (Kulak et al., 2010;
Terpstra et al., 2010), while glutathione remains approximately con-
stant (Kulak et al., 2010; Tkáč et al., 2003). In line with this are obser-
vations that young rodents are more prone to oxidative stress than
are mature animals (Lykkesfeldt, 2002) and that the developing ro-
dent brain is particularly susceptible to vitamin C deﬁciency because
of rapid cellular growth and immature antioxidant defense systems
(Lykkesfeldt et al., 2007). Indeed, ascorbate deﬁciency in early post-
natal life results in impaired neuronal development and spatial mem-
ory deﬁcits (Tveden-Nyborg et al., 2009), which are associated with
brain areas that normally contain higher levels of ascorbate, namely
the hippocampus and cortex (Rice, 2000).
Rodents such as mice and rats, in contrast to humans, are able to
endogenously synthesize ascorbate and can adapt its synthesis
according to demand (Rice, 2000). As the organism and its antioxi-
dant systems mature, less ascorbate is needed and synthesis is
down-regulated (Kulak et al., 2010).
Translational research from animal models to clinical applications
The discovery of sensitive biomarkers that indicate disease pro-
gression is useful for identiﬁcation of beneﬁcial treatments. A bio-
marker ideally is sensitive and speciﬁc for a particular disorder and
manifests changes before irreversible structural alterations take
place. Blood is the most convenient source of biomarkers for patholo-
gy assessment. This is however limited to the use in diagnosis of
autoimmune, metabolic or genetic disorders that affect the CNS. In
addition, neurodegeneration processes are in most cases not reﬂected
in peripheral tissues as they affect only regions of the brain. MR
methods are nowadays the best non-invasive tools to address cere-
bral status or function. However, similar metabolic alterations can
occur in different neurological disorders and may lead to similar
modiﬁcations in 1H NMR spectra acquired in vivo. Thus, instead of de-
termining each metabolite per se, the neurochemical proﬁle mapped
throughout the brain using e.g. spectroscopic imaging must be
viewed as a whole biomarker consisting of not only the neurochemi-
cal concentrations but also the regional speciﬁcity associated to each
CNS disorder.
As discussed above, brain NAA concentration increases during de-
velopment to adulthood in rodents and humans and reduces upon
progression of neurodegeneration. With NAA, also myo-inositol may
be modiﬁed upon neuronal injury and degeneration, being usually as-
sumed to be a marker of gliosis. Therefore, these are examples of eas-
ily detectable metabolites at low magnetic ﬁelds and often taken as
markers for tissue differentiation or progression of neurological
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homeostasis and cell survival, and increasingly viewed as central
players in several aging-related neurodegenerative diseases (Lin and
Beal, 2006). Consequently, evaluation of neurochemicals that are di-
rectly related to bioenergetics is important in neurodegeneration. For
these, however, quantiﬁcation requires use of higher magnetic ﬁelds.
Most MR scanners available for clinical routine are operating at a
low magnetic ﬁeld. Therefore the extensive neurochemical proﬁle
observed in animal studies is not directly applicable to the clinical en-
vironment. Nevertheless, even at 1.5 T, several metabolites are distin-
guishable in 1H NMR spectra at short echo time. Then, analysis with
LCModel (Stephen Provencher Inc., Oakville, Ontario, Canada) or
similar algorithms permits to measure several components and
quantify compounds like creatine (comprising both phosphorylated
and unphosphorylated forms), NAA, myo-inositol, total choline-
containing compounds, and glutamate plus glutamine (the so called
“Glx”). In a clinical 3.0 T system, Mekle et al. (2009) achieved spectral
resolution sufﬁcient to quantify a neurochemical proﬁle composed of
14 metabolites. The samewas possible at 7.0 T in half of the scan time,
i.e. 4 min (Gambarota et al., 2009; Mekle et al., 2009; Tkáč et al.,
2009). At 9.4 T, with a 3 min scan, the same neurochemical proﬁle
was determined (Deelchand et al., 2010). This means that, at high
ﬁeld, the variety of neurochemicals detected in the human brain in-
creasingly resemble those in rodents. Therefore, this reliable tool
opens a new window for diagnosing neurological disorders and mon-
itoring therapy outcomes. Furthermore, because the exact same tool
can be applied to rodents, 1H NMR spectroscopy in animal models
with speciﬁc neuropathological phenotypes is an excellent basis for
translational research aiming to understand biochemical mechanisms
of disease development and progression.
Hungtinton's disease
Huntington's disease (HD) is a neurodegenerative illness caused by
a polyglutamine expansion mutation at the N-terminal end of the hun-
tingtin protein. GABAergic medium-sized spiny neurons in the striatum
are particularly affected and progressively lost with disease progres-
sion, which has been associated with mitochondrial dysfunction in
both neurons and glia (e.g. Lin and Beal, 2006; Oliveira, 2010). Trans-
genic mice models have been created with mutated huntingtin to
study the mechanisms of the disease and deﬁnitively suggest compro-
mised mitochondrial dysfunction as a hallmark of HD (reviewed in
Oliveira, 2010). The neurochemical proﬁle of such mice reveal consis-
tent modiﬁcations (Jenkins et al., 2000, 2005; Tkáč et al., 2007;
Zacharoff et al., 2011). In the R6/2 transgenic mousemodel of HD, stria-
tal concentrations of creatine, glycerophosphorylcholine, glutamine
and glutathione were found to be increased and NAA levels decreased
(Jenkins et al., 2000; Tkáč et al., 2007). Further development of the dis-
ease leads to additionalmodiﬁcations, namely increased concentrations
of phosphocreatine, taurine, ascorbate, glutamate, andmyo-inositol and
decreased phophorylethanolamine (Tkáč et al., 2007). From these alter-
ations, reduced NAA concentrationwas found to be consistently related
to striatal neuron dysfunction and to accentuatewith progression of the
disease phenotype andwith polyglutamine expansion length, aswell as
gene expression levels and protein context (Jenkins et al., 2005). In-
creased GSH, ascorbate and taurine appear as counter-regulatory re-
sponse HD associated oxidative stress (Choo et al., 2005). Modiﬁcation
of relative phospholipid levels indicate altered cell membrane turnover,
which is consistent with changes in membrane properties of medium-
sized spiny neurons that compromise integrity of themembrane poten-
tial (Klapstein et al., 2001). Glutamine and glutamate alterations sug-
gest the impaired neurotransmission and glutamate–glutamine
cycling, while increased creatine and phosphocreatine are the reﬂection
of impaired mitochondrial bioenergetics and reduced oxidative phos-
phorylation (Oliveira, 2010). Recently, an elegant study in the R6/2
model of HD demonstrated that neurochemical alterations measuredby MRS anticipate structural deterioration detectable in MR images
(Zacharoff et al., 2011), indicating that the neurochemical proﬁle may
be used as biomarker for early therapeutic decisions.
Mitochondrial toxins like 3-nitropropionic acid (3-NP) and malo-
nate, functioning as inhibitors of the complex II of mitochondrial re-
spiratory chain, effectively induce behavioral changes and selective
striatal lesions in animals mimicking symptoms of HD. In fact, like
in the striatum of R6/2 transgenic mice, 3-NP-treated rats display re-
duced striatal NAA levels (reviewed in Lee and Chang, 2004). In ac-
cordance with the expected mitochondrial impairment, the inhibitor
of the respiratory chain 3-NP leads to increased striatal lactate concen-
tration (e.g. Jenkins et al., 1996; Lee and Chang, 2004; Tsai et al., 1997).
Parkinson's disease
Parkinson's disease (PD) is a disorder of the central nervous sys-
tem associated with degeneration of dopaminergic neurons located
in the ventral mesencephalon, which impairs motor skills, cognitive
processes, and other mental functions. Although the mechanisms by
which these neurons degenerate in PD are poorly understood, indi-
rect evidence suggests involvement of glutamatergic mechanisms in
the pathogenesis of this disorder. PD not only affects basal ganglia,
the pathology is accompanied by functional changes of cerebral
motor cortex. Decreased NAA to creatine ratio have been extensively
observed in cerebral areas of PD patients (e.g. Camicioli et al., 2007;
Lucetti et al., 2001, 2007; Taylor-Robinson et al., 1999; Tedeschi
et al., 1997; reviewed by Clarke and Lowry, 2001). Lower signal corre-
sponding to choline-containing compounds was also reported in cor-
tical areas of PD patients (Lucetti et al., 2007; Taylor-Robinson et al.,
1999). Glutamate to creatine ratio was found reduced in the anterior
cingulate gyrus of PD patients in one study (Grifﬁth et al., 2008). This
particular study however failed to identify reduced NAA levels that
have been frequently reported throughout different brain areas in
PD. As for other neurodegenerative disorders, mitochondrial dysfunc-
tion contributes to neuronal degeneration in PD patients (Lin and
Beal, 2006). Accordingly, a reduction of high-energy phosphates and
increased lactate concentration was observed in several brain areas
of PD patients when compared to healthy subjects (Hattingen et al.,
2009; reviewed in Henchcliffe et al., 2008).
NMR spectroscopy studies in animal models of PD have been
largely limited to administration of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) or its active metabolite 1-methyl-4-
phenylpyridinium (MPP+), a neurotoxin that leads to destruction of
dopaminergic neurons in the substantia nigra, causing permanent
symptoms of PD (reviewed in Henchcliffe et al., 2008). Reduced
NAA and increased lactate levels were observed in the striatum or
substantia nigra of mouse (Boska et al., 2005; Koga et al., 2006), rat
(Jenkins et al., 1996; Storey et al., 1992), feline (Podell et al., 2003),
canine (Choi et al., 2011) or primate (Brownell et al., 1998) MPTP/
MPP+-intoxicated models, suggesting neuronal loss andmitochondri-
al dysfunction. GABA was suggested to be either increased (Chassain
et al., 2008, 2010) of reduced (Storey et al., 1992) after MPTP/MPP+
treatment. Increased concentration of both glutamate and glutamine
was proposed in the striatum of animal models of PD compared to con-
trols (Chassain et al., 2008, 2010; Podell et al., 2003), as consequence of
excitotoxicity and/or impaired glutamatergic neurotransmission. Rats
injected with 6-hydroxydopamine and ascorbate in the substantia
nigra, which also mimic phenotypes of PD, were found to have reduced
NAA to creatine ratio in the frontal cortex, associated with synaptic de-
generation and dopaminergic loss (Hou et al., 2010).
Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegen-
erative disease caused by the degeneration of motor neurons, thus
also known as motor neuron disease. The neuronal marker NAA has
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rodegeneration in ALS. Compared to healthy individuals, ALS patients
show reduced levels of NAA the primary motor cortex (Gredal et al.,
1997; Han and Ma, 2010; Nelles et al., 2008; Pioro et al., 1994; Pohl
et al., 2001; Sarchielli et al., 2001; Suhy et al., 2002; Wang et al.,
2006) and brain stem (Cwik et al., 1998; Pioro et al., 1999). Reduced
NAA to total creatine ratio in motor cortex of ALS patients correlates
with ALS Functional Rating Scale that depicts ALS progression (Sivák
et al., 2010). Similarly, a decrease in ratio of NAA to choline-
containing compounds in motor cortex is associated and correlated
with disease progression in ALS patients (Pohl et al., 2001). Consis-
tent with excitotoxicity, increased Glx levels were found in the
brain stem, namely in medula oblongata (Pioro et al., 1999), and in
the motor cortex (Han and Ma, 2010) of ALS patients compared to
healthy subjects.
ALS patients were monitored upon treatment with riluzole and
amelioration of the ratio of NAA to creatine was observed in motor
cortex (Kalra et al., 1998, 2006) strengthening the hypothesis that
NAA levels are a measure of neuronal integrity. Conversely, treatment
with gabapentin failed to prevent neurodegeneration as depicted by a
progressive decrease of NAA levels (Kalra et al., 2003). Treatment
with minocycline could also prevent further decline in NAA to crea-
tine ratio in brain stem and motor cortex, suggesting prevention of
the progressive neurodegeneration (Khiat et al., 2010). However,
the appropriate control group with healthy individuals was not ana-
lyzed in this particular study.
Transgenic mice with the superoxide dismutase mutation G93A
have been widely utilized as an animal model of familial ALS. The
brain of these mice shows reduced NAA levels (Pioro et al., 1998;
Niessen et al., 2007). Increased Glx in cortical areas was also sug-
gested by Andreassen et al. (2001). Recently, in vivo 1H NMR spec-
troscopy at 9.4 T revealed that both glutamate and glutamine may
be increased in brain stem, motor cortex or striatum of these mice
at different stages of the disease, e.g. increased glutamate concentra-
tion followed by accumulation of glutamine (Lei et al., 2011).Alzheimer's disease
Alzheimer's disease (AD) is a progressive neurodegenerative dis-
order and the most common form of dementia in elderly, occurring
with increased incidence in a continuously aging population. In vivo
1H NMR spectroscopy has opened new possibilities to assess metabol-
ic and functional correlates of dementia in research and clinical set-
tings, as well as prediction of future cognitive decline (Kantarci,
2007). By utilizing MRS, reduced NAA and increased myo-inositol con-
centrations have been consistently found in the brain of AD patients
compared to cognitively healthy elderly individuals and to be correlated
to decline in cognitive performance (e.g. Chantal et al., 2002, 2004;
Huang et al., 2001; Kantarci et al., 2004; Klunk et al., 1998; Jessen
et al., 2000, 2009; Meyerhoff et al., 1994; Miller et al., 1993;
Mohanakrishnan et al., 1997; Pfefferbaum et al., 1999a,b; Rose et al.,
1999; Schuff et al., 2002; Watanabe et al., 2010). While NAA indicates
loss of neuronal integrity,myo-inositol has been interpreted as amarker
of gliosis (see discussion above). Most of these clinical MRS studies de-
terminedNAA andmyo-inositol contents as a ratio to other peaks in the
1H NMR spectra, namely choline and creatine. However, some studies
found elevated choline (Kantarci et al., 2004; Meyerhoff et al., 1994;
Pfefferbaum et al., 1999a,b) and creatine (Huang et al., 2001) signals
in 1H NMR spectra from the brain of AD patients compared to healthy
controls. Increases in GPC levels in post-mortem cortical gray matter
measured analytically from severely demented AD brains have been at-
tributed to membrane breakdown (Nitsch et al., 1992). However, cho-
line and creatine resonances were reduced in certain brain areas of AD
patients compared to controls (Chantal et al., 2002; Watanabe et al.,
2010).The concentration of NAA in brain areas of patients with mild cog-
nitive impairment was found to be lower than that in the brains of AD
patients but higher than that of healthy subjects (e.g. Jessen et al.,
2009; Kantarci et al., 2007; Watanabe et al., 2010). Furthermore,
NAA decrease has been suggested to correlate with cognitive decline
from light dementia to AD (e.g. Chantal et al., 2002, 2004; Pilatus
et al., 2009). These ﬁndings suggest a positive correlation between
NAA levels and cognitive performance.
Impaired cerebral energy metabolism is known to occur in AD pa-
tients (reviewed in Ferreira et al., 2010). Accordingly, in addition to
these neurochemical markers, after glucose administration, glucose
is observed in the brain of AD patients at higher levels than healthy
subjects (Haley et al., 2006). The increased brain glucose levels thus
likely reﬂect reduced glucose metabolism, although the increased
contribution of high concentrated glucose in CSF due to atrophy
may contribute.
Gene mutations associated with early-onset familial AD directly
affect amyloid metabolism (Selkoe, 1995). Namely, these are muta-
tions associated with the β-amyloid precursor protein (APP), prese-
nillin 1 (PS1) and presenillin 2 (PS2). Murine models of AD have
been created by inserting one or more of these human mutations
into the mouse genome and have been explored by in vivo 1H NMR
spectroscopy.
Double transgenic mice expressing human mutant APP and
human mutated PS1 (APP/PS1) display decreased glutamate and
NAA concentrations in the brain, particularly in the hippocampus,
that were observed at the time where hippocampal volume was al-
ready reduced but amyloid plaques were not yet present (Choi
et al., 2010; Marjanska et al., 2005; Oberg et al., 2008). Later, upon
visible amyloid deposits, these mice also presented increased brain
myo-inositol to creatine ratio, when compared to wild type mice
(Jack et al, 2007), accompanied by astrogliosis as detected by histo-
chemistry methods (Chen et al., 2009). Increased myo-inositol and
glutamine and decreased NAA and glutamate were reported to
occur in the cortex of these mice. Additionally, it was found that
once amyloid plaques are observed, NAA levels are inversely associat-
ed to the area of cortex occupied by plaques (Choi et al., 2010).
Dedeoglu et al. (2004) but not Marjanska et al. (2005) reproduced
these ﬁndings in mice possessing only the mutated APP gene. Both
authors reported, however, higher cerebral taurine to creatine ratio
in the brain of APP transgenic mice compared to wild type mice
(Dedeoglu et al., 2004; Marjanska et al., 2005). These results were
conﬁrmed by in vitro NMR spectroscopy of brain extracts, in which
glutathione levels were additionally found to be lower than in con-
trols (Dedeoglu et al., 2004).
In summary, compared to healthy subjects, AD patients display
lower NAA and increased myo-inositol in the brain, reﬂecting disease
progression. These observations are also mimicked in animal models
of AD. However, contradictory results have appeared regarding
some metabolic observations and their regional distribution.
Hypoxic and ischemic diseases
A drop in cerebral perfusion reduces glucose and oxygen supply,
thus starting a cascade of electrophysiological and metabolic events
leading to cell injury, loss of function and then neurodegeneration.
Profound metabolic changes occur during ischemia and after, in
early stages of re-oxygenation, some metabolic alterations persist
(Berthet et al., 2011; Lei et al., 2009), particularly dramatically in-
creased lactate levels that can be further used by neurons upon reper-
fusion (Berthet et al., 2009). In addition, during ischemia there is a
decrease in glutamate and a transient glutamine increase, likely to
be linked to the excitotoxic release of glutamate and conversion
into glial glutamine. Interestingly, decreases in NAA, as well as in
the osmolyte taurine, exceeded those in neuronal glutamate, suggest-
ing that the putative neuronal marker NAA is a sensitive marker
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more profound concentration decreases are detected, reﬂecting a
disruption of cellular function. Thus, early changes in markers of
energy metabolism, glutamate excitotoxicity, osmolarity deregulation
and neuronal viability can be detected with high precision non-
invasively in mice after stroke, and provide a better understanding
of the sequential early changes in the brain parenchyma after ische-
mia (Lei et al., 2009), which could be used to identify new targets
for neuroprotection and deﬁning metabolic markers of tissue viability
after stroke (Berthet et al., 2011; Bruhn et al., 1989; Gideon et al.,
1992, 1994).
As the neurochemical proﬁle is modiﬁed strongly during cerebral
development (Kulak et al., 2010; Tkáč et al., 2003), also the reaction
to an acute injury like ischemia is distinct if occurring some days
after birth or during adulthood. In rat pups after birth (at P4), ische-
mia triggers an acute decrease of most of the metabolite concentra-
tions and an increase in lactate, followed by a recovery phase with
minor metabolic modiﬁcations in spite of abnormal brain develop-
ment (at P25) (van de Looij et al., 2011a). It was observed that the in-
crease of lactate concentration at P4 correlated with the cortical loss
at P25 (van de Looij et al., 2011a), giving insight into the early predic-
tion of long-term cerebral alterations following a moderate insult
caused by hypoxia or ischemia, which could be of interest in clinical
practice.
Recurrent exposure to hypoxia periods during development leads
to the establishment of chronic neurochemical alterations of a differ-
ent nature, particularly aspartate, creatine, phosphocreatine, GABA,
glutamate, glutamine, glutathione, myo-inositol, NAA, phosphory-
lethanolamine (Raman et al., 2005; Rao et al., 2006). The increased
PCr/Cr and Glu/Gln ratios and GABA levels are consistent with de-
creased brain energy consumption and impaired neurotransmission.
Decreased NAA and phosphorylethanolamine suggest reduced neuro-
nal integrity and phospholipid metabolism. These hippocampal alter-
ations suggest impaired neurochemical processes that reﬂect
development of cognitive deﬁcits, which are observable in infants
suffering from chronic hypoxia (e.g. Kirkham and Datta, 2006).
Lactate and NAA are therefore metabolic markers of strong inter-
est in the case of ischemic diseases. In fact, it has been shown that
these markers are valuable predictors of stroke outcome and provide
prognostic information complementary to imaging techniques (e.g.
Gideon et al., 1994; Parsons et al., 2000; Pereira et al., 1999;
Wardlaw et al., 1998). Recently, a study in experimental models of is-
chemia revealed neurochemical modiﬁcations, namely in NAA, gluta-
mate and taurine concentrations, at an early time point after
reperfusion, when structural abnormalities were absent and/or unde-
tectable by MRI methods (Berthet et al., 2011). Interestingly, the type
and intensity of these neurochemical modiﬁcations were strong pre-
dictors of the lesion volume measured 1 day after the ischemic insult
(Berthet et al., 2011). Further research may lead to the establishment
of metabolic markers in stroke patients predicting the outcome after
stroke, thus facilitating appropriate therapeutic decisions based on
1H NMR spectroscopy data.Diabetic encephalopathy
Diabetes mellitus is a metabolic disease characterized by hyper-
glycemia and its treatment with insulin frequently results in hypogly-
cemia episodes. Both hyper- and hypoglycemia affect brain function
and may lead to cognitive dysfunction and dementia. Experimental
diabetic conditions cause deﬁcits in spatial learning and synaptic
plasticity (e.g. Biessels et al., 1996), synaptic degeneration (e.g.
Duarte et al., 2006, 2009a; Grillo et al., 2005) and increased astrocyte
reactivity and proliferation (e.g. Baydas et al., 2003; Saravia et al.,
2002) particularly in the hippocampus, a structure involved in learn-
ing and memory processing. These structural and functionalmodiﬁcations are likely to lead to altered cerebral metabolism
(Duarte et al., 2009a).
Duarte et al. (2009a) found that diabetic rats under chronic hyper-
glycemia, induced by STZ administration, display a plethora of meta-
bolic alterations in the hippocampus, most of which are normalized
upon acute restoration of euglycemia. Some of the metabolites more
affected by hyperglycemia were myo-inositol, taurine and creatine,
which are considered major organic osmolytes regulating brain os-
motic adaptation, suggesting that such alterations of the neurochem-
ical proﬁle may be related to regulation of osmolarity. Similar results
were obtained in Goto–Kakizaki rats, an experimental model of insu-
lin resistance and type 2 diabetes (Duarte et al., 2009c). Although os-
molarity regulation primarily relies on electrolytic balance, it is
followed by a delayed response of organic osmolytes (e.g. Verbalis,
2010). Therefore, under chronic hyperglycemia, the accumulation of
organic osmolytes in the hippocampus is suitable to avoid ion-
induced perturbation of protein function. Consistent with this, a
high concentration of myo-inositol has also been reported in the hip-
pocampus of Zucker diabetic fatty rats compared to controls (van der
Graaf et al., 2004) and in the brain of diabetes patients (Geissler et al.,
2003; Kreis and Ross, 1992). Thus, the study of the neurochemical
proﬁle supports the hypothesis that hyperglycemia-induced hippo-
campal dysfunction mainly involves deregulation of osmotic balance
rather than modiﬁcation of primary metabolism. It is important to
note that, although myo-inositol has been suggested as a marker of
gliosis in several neurological disorders, in the study by Duarte et al.
(2009a) it did not correlate with other markers of astrocytosis.
Other studies have not detected a relation between in vivo cerebral
myo-inositol concentrations and gliosis detected by immunohisto-
chemical methods (Kim et al., 2005; Kunz et al., 2011). On the other
hand, cerebral myo-inositol was found to correlate with gliosis in
AD (e.g. Chen et al., 2009), thus this may be, in fact, a case where
eventual strong correlations do not necessarily imply causal
relationships.
Schizophrenia
Schizophrenia is a neurodevelopmental disorder with both genet-
ic and environmental aspects, involving functional alterations on both
dopaminergic and glutamatergic neurotransmission, and associated
with a dysfunctional redox system (Do et al., 2009). GSH, the major
cellular redox regulator and antioxidant, is decreased in cerebrospinal
ﬂuid, medial prefrontal cortex (Do et al., 2000; Matsuzawa and
Hashimoto, 2011) and post mortem striatum (Yao et al., 2006) of
schizophrenia patients.
Schizophrenia patients display brain metabolic alterations, partic-
ularly increased glutamine and glutamate in anterior regions of the
cortex (Shirayama et al., 2010; Bustillo et al., 2009; Tayoshi et al.,
2009; Lutkenhoff et al., 2008). Other reports suggested altered NAA,
creatine and choline in the thalamus (Yoo et al., 2009) and hippocam-
pus (Lutkenhoff et al., 2008).
Altered glutamatergic neurotransmission leads to altered levels of
glutamine, glutamate and most notably of glutamine-to-glutamate
ratio, as observed in 1H NMR spectra from anterior brain areas of
schizophrenia patients (Shirayama et al., 2010; Bustillo et al., 2009;
Tayoshi et al., 2009; Lutkenhoff et al., 2008), and similar observations
have been reported in experimental models of schizophrenia. A
recent study reported elevated glutamine to glutamate ratio and
changed energy metabolism in prefrontal cortex of rats with NMDA
receptor hypofunction, a rodent model that mimics schizophrenia
symptoms (Iltis et al., 2009).
Mice with sustained GSH deﬁcit induced by genetic deletion of its
key synthesizing enzyme, glutamate-cysteine ligase modulatory sub-
unit, also display increased cortical glutamate, glutamine and
glutamine-to-glutamate ratio, consistent with impaired glutamater-
gic neurotransmission, and increased NAA and myo-inositol, in
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tured in the schizophrenia brain (Do et al., 2009). Interestingly, in ac-
cordance the neurodevelopmental character of schizophrenia, these
neurochemical alterations were most prominent during development
and pre-pubertal age rather than in mouse adulthood (Duarte et al.,
2011). In adulthood, increased cortical lactate levels were consistent
with impaired mitochondrial metabolism, known to occur upon
redox deregulation (Duarte et al., 2011).Ataxia
Hereditary and sporadic neurodegenerative ataxias are a geneti-
cally and clinically heterogeneous group of movement disorders
that affect particularly the cerebellum. In addition to cerebellar atro-
phy, clinical MRS studies have revealed that neuronal degeneration
and inﬂammatory gliosis are associated to a decreased NAA to crea-
tine ratio and increased myo-inositol to creatine ratio (Boesch et al.,
2001, 2007; D'Abreu et al., 2009; França et al., 2009; Guerrini et al.,
2009; Mascalchi et al., 2002; Viau et al., 2005). Recently, in a study
with patients with Friedreich's ataxia and with ataxia with oculomo-
tor apraxia type 2, absolute quantiﬁcation of 1H NMR spectra from the
vermis showed a decrease in NAA and glutamate and an increase in
myo-inositol and glutamine concentrations (Iltis et al., 2010). Similar
observations were reported in another recent MRS study with pa-
tients affected by spinocerebellar ataxia type 1 (SCA1) (Oz et al.,
2010a). This evidence for increased glutamine supports the known
gliotic events. However, increased glutamine associated to reduced
glutamate concentration suggests impaired glutamatergic neuro-
transmission. Concentrations of NAA and myo-inositol as well as the
ratio of glutamine to glutamate in cerebellar lesions appear as the
most robust biomarkers for ataxia and correlate well with ataxia
scores (Iltis et al., 2010; Oz et al., 2010a,b).
Although mouse models of hereditary ataxias have been generat-
ed aiming at understanding the biochemical mechanisms of this dis-
order, not many studies were dedicated to the characterization of-50 0 50 100 150 200
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Fig. 5. Typical determination of glucose transport kinetics by in vivo 1H NMR spectroscopy in
plasma glucose levels with glucose resonances depicted in red (Glc). Dynamic and steady-s
spectively (see details in Duarte et al., 2009a,b).their cerebral metabolism. The neurochemical proﬁle in the cerebel-
lum of a mouse model of SCA1 was studied at 9.4 T (Oz et al.,
2010c). In this study, compared to wild-type mice, the transgenic
model presented features of the human disorder, namely reduced
NAA and glutamate and increased myo-inositol concentrations.
These modiﬁcations correlated with pathology progression as deter-
mined by behavioral and histological analyses (Oz et al., 2010c). In
addition, the authors reported reduced taurine, which may be used
to balance increased myo-inositol, and increased glucose and lactate
levels (Oz et al., 2010c). In fact, higher glucose levels were found in
the cerebrospinal ﬂuid of some ataxia patients, compared to healthy
subjects (Iltis et al., 2010).
To detail speciﬁc metabolic abnormalities and ﬁnd robust bio-
markers in clinically different ataxia types (Oz et al., 2010a,b; Viau
et al., 2005), higher magnetic ﬁelds are of value for unraveling alter-
ations in a greater number of neurochemicals in the brain of ataxia
patients.Cerebral function by dynamic 1H MRS
Although in vivo 1H NMR spectroscopy typically provides a com-
position of biochemicals in the brain that are often used as markers
of development, differentiation and degeneration, it can be applied
dynamically to evaluate cerebral functions that involve modiﬁcation
of metabolite concentrations. In this section, we describe some
examples.Determination of blood–brain-barrier glucose transport
Brain function relies on adequate delivery of substrate, mainly glu-
cose and oxygen, from the blood stream. Glucose is detectable by 1H
NMR spectroscopy. Therefore, its transport across the blood–brain-
barrier (BBB) can be measured non-invasively. Several studies have
measured glucose transport and consumption by detecting brain0 10 20 30 40
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the rat brain under α-chloralose anesthesia. Panel A shows spectrum acquired at high
tate determination of cerebral glucose transport are represented in panels B and C, re-
356 J.M.N. Duarte et al. / NeuroImage 61 (2012) 342–362glucose signals in vivowith 1H NMR spectroscopy (e.g. Gruetter et al.,
1996, 1998; Mason et al., 1992).
Most in vivo studies employing 1H NMR spectroscopy to deter-
mine glucose transport across the BBB have been performed at
steady-state. For that, in vivo 1H NMR spectra are acquired at different
stable glycemia levels. In these experiments, a nearly linear relation
between brain and plasma glucose concentrations has been observed
in humans (Gruetter et al., 1998) and in rodents (e.g. Choi et al., 2002;
Duarte et al., 2009a,b; Lei et al., 2010a), within the normal physiolog-
ical range. This relation was further conﬁrmed with biochemical
determination of glucose in brain extracts (comparison in Duarte
et al., 2009b).
Although the kinetics can be determined from brain glucose con-
tent, the afﬁnity constant of glucose transport is often difﬁcult to
measure (e.g. Choi et al., 2002; Lei and Gruetter, 2006; Seaquist
et al., 2001) and the transport rate is determined relative to the glu-
cose consumption rate. Thus, often a constant cerebral metabolic
rate of glucose (CMRglc) is assumed to determine the apparent maxi-
mal rate of glucose transport (Tmax) (e.g. Choi et al., 2002; Duarte
et al., 2009a,b; Gruetter et al., 1998; Lei et al., 2010a). However,
Gruetter et al. (1996) measured glucose transport kinetics using 1H
NMR difference spectroscopy after a rapid increased in plasma glu-
cose concentration, i.e. by acutely displacing glucose levels from
steady-state. This method had the advantage of quantifying 1H NMR
spectra with only glucose resonances and allowed independent de-
termination of both Tmax and CMRglc (Gruetter et al., 1996). Therefore,
in vivo dynamic measurement of cerebral glucose concentration upon
a challenge of plasma glucose homeostasis potentially allows distinc-
tion of both glucose transport and consumption in the brain. Typical
experiments for BBB transport determination are depicted in Fig. 5.
Although glucose is the main substrate for the brain, other com-
pounds like ketone bodies, acetate or lactate can be used as a source
of energy to maintain cerebral functions when glucose supply is lim-
iting. Because they can be detected in 1H NMR spectra (Duarte et al.,
2009a; Lei et al., 2010a; Xin et al., 2010b), a similar approach could
be used to determine their transport rates across the BBB (e.g. Pan
et al., 2001).
Functional 1H NMR spectroscopy (fMRS)
Functional MRI (fMRI) measures the hemodynamic response, i.e.
changes in local cerebral blood ﬂow, blood volume and oxygenation,
related to neuronal activity in the brain. In the realm of human func-
tional studies, 1H NMR spectroscopy has been used to report the time
course of brain metabolites, mostly lactate, during such type of stim-
ulation. Increase in lactate concentration was reported upon sus-
tained visual cortex stimulation by Prichard et al. (1991), suggesting
a stimulation-induced increase in cerebral metabolic rate of glucose.
This observation was further conﬁrmed (e.g. Frahm et al., 1996;
Kuwabara et al., 1995; Sappey-Marinier et al., 1992) and suggested
to be associated to other metabolic modiﬁcations like a decrease in
glucose concentration, as detected by in vivo 1H NMR spectroscopy
(Frahm et al., 1996; Chen et al., 1993; Merboldt et al., 1992), and in
phosphocreatine versus inorganic phosphate in 31P NMR spectra
(Sappey-Marinier et al., 1992).
With the increase in sensitivity and spectral resolution at high
magnetic ﬁeld, 1H NMR spectroscopy in the human visual cortex
allowed to detect, in addition to lactate and glucose modiﬁcations,
an increase in glutamate and a decrease in aspartate levels during
stimulation (Mangia et al., 2007), suggesting modiﬁcations in the
ﬂow through the malate–aspartate shuttle, possibly linked to adjust-
ments in redox potential upon increased cerebral glucose consump-
tion. Similar alterations of lactate, glutamate and aspartate
concentrations as well as increased alanine levels have been reported
in the cortex of conscious rats upon sensory stimulation (Dienel et al.,
2002). However, using in vivo 1H NMR spectroscopy in rats under α-chloralose anesthesia, Xu et al. (2005) found that sensorial stimula-
tion could lead to an increase in glutamine and a decrease in
glutamate, myo-inositol, and phosphocreatine/creatine ratio in the
focally activated primary sensory cortex, albeit the modiﬁcations in
lactate and glucose concentrations upon cerebral activation were
not detected. 1H[13C] NMR spectroscopy studies upon infusion of
13C-enriched glucose measured an increased tricarboxylic acid cycle
ﬂux (VTCA) in focally activated primary sensory cortex during forepaw
stimulation (Hyder et al., 1996, 1997; Yang and Shen, 2006) that is
certainly linked to the increased cerebral metabolic rates of glucose
(CMRglc) and oxygen (CMRO2), as well as in humans (Chen et al.,
2001). Altogether, these studies indicate that the blood-oxygen-
level dependence (BOLD) fMRI signal-change is associated with an in-
crease in oxidative metabolism.
Dynamic evaluation of tumor metabolism
Brain tumors are characterized by typical neurochemical proﬁles
that are type and grade dependent and, therefore, the beneﬁcial asso-
ciation of 1H NMR spectroscopy to MRI techniques may increase accu-
racy in diagnosis than using MRI alone (Howe and Opstad, 2003;
Möller-Hartmann et al., 2002; Tate et al., 2006). Tumors are known
to display increased primary metabolism and other altered metabolic
ﬂuxes, and this property has been explored as way of contributing for
tumor diagnostics (Simões et al., 2008, 2010). A mouse model of gli-
oma was challenged with acute hyperglycemia thus not only measur-
ing the steady-state neurochemical proﬁle but determining the
reaction of the tumor to a metabolic perturbation (Simões et al.,
2008). Furthermore, by using spectroscopic imaging, the response of
the tumoral tissue to the metabolic challenge could be compared to
the surrounding healthy tissue (Simões et al., 2010). By induction of
acute simultaneous hyperglycemia and hypothermia stimuli, Simões
et al. (2010) identiﬁed increased glucose levels in the tumor and
heterogeneity of tumor response at the tumor center or penumbra.
Similarly, with 13C NMR spectroscopy upon 13C-enriched glucose ad-
ministration, increased glucose and lactate signals were observed in
the tumor compared to non-tumor tissue (Ross et al., 1988; Terpstra
et al., 1998a,b; Wijnen et al., 2010b). In these studies, reduced 13C
incorporation in to glutamate was observed in the tumor (Wijnen et
al., 2010b) as result of reduced TCA cycle ﬂux. All together, these
observations are the result of increased BBB permeability and higher
glycolytic metabolism in tumors. Further investigations are needed to
identify if different tumor types and grade have speciﬁc responses to
acute metabolic challenges.
Concluding remarks and future directions
NMR spectroscopy no longer admits a clinical neuroscience that is
divorced from basic research, as it perfectly bridges them. 1H NMR
spectroscopy can be applied in vivo and localized in the brain to reli-
ably detect a neurochemical proﬁle comprising several biomarkers of
interest, that can be used for diagnostic procedures and therapy mon-
itoring due to its non-invasive character.
As depicted from the examples described above, most data from
clinical studies are acquired with long echo times that lead to simpli-
ﬁcation of the acquired spectra but also cause loss of informative
content in the MRS scans. In addition, many clinical cases are scanned
with low spectral resolution. This, together with high inter-subject
variability and often small number of scanned subjects, has possibly
led to conﬂicting observations in the realm of CNS disorders. Con-
versely, by using short echo times and acquiring high quality in
vivo 1H NMR spectra, an extended neurochemical proﬁle can be
determined.
NMR spectroscopy can be further extended to spectroscopic imag-
ing with spatial resolution in the μL range in the rodent brain, being
comparable to the spatial resolution of animal PET imaging but with
357J.M.N. Duarte et al. / NeuroImage 61 (2012) 342–362the advantage of detecting simultaneously a wide range of molecules.
Because pathologies affecting the CNS lead to alteration of this ex-
tended composition of neurochemicals with speciﬁc regional inci-
dence, mapping the neurochemical proﬁle throughout the brain
using spectroscopic imaging may be of added value for diagnosis
and therapy monitoring.
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